Transoral Outlet Reduction in Treating Dumping Syndrome after Roux-En-Y Gastric Bypass: A Systematic Review and Meta-Analysis.

Authors

Larissa Sundrum, Alida Finze, Mirko Otto, Johanna Betzler, Sebastian Schölch, Svetlana Hetjens, Christoph Reissfelder, Susanne Blank, Christine Stier

Published in

Visceral medicine. Jul 10, 2026. Epub Jul 10, 2026.

Abstract

Dumping syndrome (DS) is a frequent complication after Roux-en-Y gastric bypass (RYGB), causing gastrointestinal and neurohumoral symptoms that can significantly affect quality of life. Transoral outlet reduction (TORe) has been used in clinical practice as a therapy of DS alongside other conservative and surgical approaches. Effectiveness of different therapy options remains unclear. This meta-analysis aimed to provide an overview of the available data concerning TORe.
A meta-analysis was conducted, including ten retrospective studies identified through a literature search in five databases. All studies analyzed the resolution of DS symptoms after TORe through evaluation of the Sigstad score.
The literature search yielded 1,014 publications, of which ten retrospective studies involving a total of 320 patients met the inclusion criteria for this meta-analysis. The analysis showed that TORe led to a pooled success rate, defined as overall improvement of symptoms based on subjective patient responses or reduction of Sigstad score to <7 points of 95.59%, significant weight loss (p < 0.001), and an average reduction of Sigstad score by 8.71 points, indicating a consistent improvement in the severity of DS (p < 0.001).
This meta-analysis demonstrates that TORe can be an effective, endoluminal treatment option for DS following RYGB. However, limitations include the retrospective nature of the studies, lack of long-term follow-up, and inconsistent outcome measures. No distinction between early and late DS was observed in any of the included trials. Future research should focus on prospective trials, standardized outcomes, and comparisons with surgical options in order to fully assess the efficacy and durability of TORe. The use of additional objective primary outcome measures, such as oral glucose tolerance testing and continuous glucose monitoring, is suggested.

PMID:
42598712
Bibliographic data and abstract were imported from PubMed on 14 Aug 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.